Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kerry Cleveland

Infectious Disease Memphis, TN Medical Doctor

NPI 1114984911 CMS profile 141129

1910 Nonconnah Blvd, Suite 120, Memphis, TN 38132

Open in the dashboard

General payments

$426,308

526 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$100,807

3 holdings reported · through program year 2025

Through program year 2025, Kerry Cleveland of Memphis, TN is reported in the CMS Open Payments database as having received $426,308 across 526 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $100,807 across 3 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $75,134 86
2024 General $11,918 11
2023 General $56,748 58
2022 General $52,240 56
2021 General $22,080 25
2020 General $40,676 47
2019 General $167,513 243
2025 Ownership $807 1
2024 Ownership $50,000 1
2023 Ownership $50,000 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kerry Cleveland
  • Infectious Disease median
  • Middle half of Infectious Disease
  • National median

In program year 2025, general payments to Kerry Cleveland were reported at $75,134. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.

Show as a table
Year Kerry Cleveland Infectious Disease median Middle half National median
2019 $167,513 $190 $60–$862 $163
2020 $40,676 $124 $32–$606 $114
2021 $22,080 $148 $38–$905 $132
2022 $52,240 $166 $50–$834 $149
2023 $56,748 $171 $57–$787 $160
2024 $11,918 $176 $52–$752 $164
2025 $75,134 $188 $57–$766 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $151,653 162 payments
  2. Allergan Inc. $123,979 168 payments
  3. Merck Sharp & Dohme Corporation $117,530 153 payments
  4. Paratek Pharmaceuticals, Inc. $11,828 16 payments
  5. Cumberland Pharmaceuticals, Inc. $11,236 11 payments
  6. Pfizer Inc. $9,557 9 payments
  7. La Jolla Pharmaceutical Company $394 4 payments
  8. COMSORT, Inc $100 1 payment
  9. Insmed, Inc. $32 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $350,405 147 payments
  2. Travel and Lodging $50,944 240 payments
  3. Consulting Fee $10,803 9 payments
  4. Honoraria $7,920 2 payments
  5. Food and Beverage $6,178 125 payments
  6. Education $58 3 payments
Products named General payments · program years 2019–2025
  1. DALVANCE $133,117 148 payments
  2. ZERBAXA $89,040 112 payments
  3. AVYCAZ $81,181 109 payments
  4. TEFLARO $39,659 50 payments
  5. DIFICID $16,810 26 payments
  6. ZINPLAVA $16,810 26 payments
  7. EMBLAVEO $14,595 19 payments
  8. NUZYRA $11,828 16 payments
  9. RECARBRIO $6,833 7 payments
  10. VIBATIV $6,000 4 payments
  11. Other $12,424 21 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$52,957

Medicare's payments for the services billed

Medicare patients

157

Average age 69

Services billed

808

68 women, 89 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 69%
Chronic kidney disease 59%
Heart failure 54%
Arthritis 54%
Ischemic heart disease 50%
Atrial fibrillation 40%
Depression 39%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DALVANCE
  • AbbVie, Inc. $5,528
$5,528 — —
TEFLARO
  • AbbVie, Inc. $2,792
$2,792 — —
AVYCAZ
  • AbbVie, Inc. $2,772
$2,772 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

526 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Infectious Disease in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record